GGrantIndex
Sort

261,768 grants matching gene therapy

Solving the Valence Assignment Problem

$937,975
Kay Maxine Tye · Salk Institute For Biological Studies · R37 · FY2023 · MH

Solving the Valence Assignment Problem

$937,975
Kay Maxine Tye · Salk Institute For Biological Studies · R37 · FY2024 · MH

Solving the Valence Assignment Problem

$937,975
Kay Maxine Tye · Salk Institute For Biological Studies · R37 · FY2025 · MH

Solving the Valence Assignment Problem

$937,975
Kay Maxine Tye · Salk Institute For Biological Studies · R37 · FY2021 · MH

Solving the Valence Assignment Problem

$937,975
Kay Maxine Tye · Salk Institute For Biological Studies · R37 · FY2022 · MH

The connection of innate and adaptive anti-cancer immunity

$937,885
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis

$937,837
Laura D Attardi · Stanford University · R35 · FY2023 · CA

Next generation hybrid nucleases for precise excision of latent HIV-1 provirus

$937,745
Jeremy Luban · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AI

Next generation hybrid nucleases for precise excision of latent HIV-1 provirus

$937,745
Jeremy Luban · Univ Of Massachusetts Med Sch Worcester · R01 · FY2018 · AI

Systems biology of HIV, methamphetamine and antiretrovirals interactions

$937,707
Pietro P Sanna · Scripps Research Institute, The · R01 · FY2016 · DA

From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma

$937,650
Riccardo Dalla-Favera · Columbia University Health Sciences · R35 · FY2024 · CA

Molecular Pathogenesis of Neoplasia

$937,516
Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2019 · NS

Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy

$937,462
Irving Lerner Weissman · Stanford University · R35 · FY2020 · CA

Disease mechanism and therapies for retinal degeneration

$937,456
Tiansen Li · National Eye Institute · ZIA · FY2011 · EY

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES

$937,381
University Of Florida · P01 · FY2000 · DK

Chemical Genomics Paradigm for Epigenetic Regulation

$937,377
Ming-Ming Zhou · Icahn School Of Medicine At Mount Sinai · R01 · FY2011 · HG

Chemical Genomics Paradigm for Epigenetic Regulation

$937,377
Ming-Ming Zhou · Icahn School Of Medicine At Mount Sinai · R01 · FY2010 · HG

Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia

$937,343
Carlo M Croce · Ohio State University · P01 · FY2012 · CA

Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level

$937,314
Andrea Califano · Columbia University Health Sciences · R35 · FY2024 · CA

WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?

$937,245
Michael David Alpert · Emmune, Inc · R44 · FY2017 · AI

he 3D Platelet Bank: A Clinical-grade, Scalable, 3D Microbioreactor Bone Marrow Mimetic for Platelet Production

$937,164
Teresa Marie Desrochers · Kiyatec, Inc. · R44 · FY2017 · EB

Mechanisms of Immune-mediated Tumor Cell Destruction

$937,072
Thomas J. Sayers · Basic Sciences · Z01 · FY2007 · CA

A Pharmacochaperone-based strategy for identifying chemical probes of brain-derived orphan GPCRs

$936,860
Layton Harris Smith · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · MH

2/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)

$936,858
Catherine A Spino · University Of Michigan At Ann Arbor · U24 · FY2025 · HL

Molecular diagnosis and outcome prediction in lymphoma

$936,810
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA